Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine, GSK2282512A, (FLU Q-QIV) When Administered in Children

Trial Profile

Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine, GSK2282512A, (FLU Q-QIV) When Administered in Children

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2015

At a glance

  • Drugs GSK 2282512A (Primary) ; Hepatitis A vaccine inactivated
  • Indications Hepatitis A; Influenza A virus infections; Influenza B virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline Biologicals
  • Most Recent Events

    • 11 Dec 2013 Results published in the New England Journal of Medicine.
    • 27 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jan 2012 Actual patient number 5220 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top